Q2 2023 Business Update to Accompany Quarterly Results
Filed with ASX · · 26 pages · English
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- Activities Report and Appendix 4C - June 2023 Quarter
- Lightpoint Acquisition to Expand Telix Urologic Pipeline
- Phase II study for indication expansion of TLX250-CDx doses
- Annual General Meeting - Presentation
- Annual General Meeting - Chairman and CEO Addresses
Later from Telix Pharmaceuticals
- First Patient Dosed in Phase 3 Illuccix China Study
- 1H 2023 Appendix 4D and Interim Report
- 1H 2023 Results Presentation
- 1H 2023 Results Release
- Activities Report and Appendix 4C - September 2023 Quarter
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals